Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

STOCKHOLM, June 30, 2010 /PRNewswire/ --

- Agreement Marks Milestone in Pharmalink's Corporate Development

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

The agreement covers acquisition of one of Pharmalink's wholly owned subsidiaries and includes inter alia US, EU and Japan patents for the treatment of PPS with immunoglobulins, a US Orphan Drug Designation (ODD) for the use of immunoglobulin for the treatment of PPS and documentation of a number of clinical studies carried out in the recent years.

Johan Haggblad, Managing director of Pharmalink AB said: "This agreement marks a significant milestone in Pharmalink's corporate development. In developing a concept originally devised by academic researchers at the Karolinska Institute and seeing it through to being acquired by a world class company we have demonstrated the considerable value creation made possible by the Pharmalink model. We are very happy to see Grifols, our long standing partner, acquire and develop the PPS indication and to have played a part in bringing forward a treatment for this underserved condition."

Grifols will develop the PPS product opportunity using the acquired assets. Pharmalink will assist in technology trans
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 23, 2014 ... Review Algeria , out today and available for free ... the actors driving change and growth in the sector today. ... has scored notable successes has been in developing a homegrown ... 70 percent local production still remains some way off. A ...
(Date:12/22/2014)... The Center for Professional Innovation ... training across the life sciences industry, has partnered with ... to provide the organization's members with discounted classroom courses, ... the more than 350 sessions across 80 course titles. ... when registering for a public course at ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
(Date:12/22/2014)... Memphis, TENN (PRWEB) December 22, 2014 ... with Donor Egg Bank USA , a network ... the country. Through this partnership, patients have fast access ... for in vitro fertilization, IVF . Fertility Associates of ... to offer this fertility treatment option. , Dr. ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... drug development company specialized in oncology and endocrinology, announced ... direct offering of US$12.1 million of units ... to certain institutional investors. Net proceeds from this offering, ...
... Fla. , June 21 Dyadic International, ... cutting-edge C1 platform technology addresses the needs of the ... scale which efficiently convert biomass into ethanol and other ... engaged the influential consulting firm, The Abraham Group, to ...
... WA , and VANCOUVER , June 21 ... ) announced today the initiation of a Phase 3 ... candidate being developed for the treatment of castrate-resistant prostate ... Cancer SATURN Trial, is the first of three Phase ...
Cached Biology Technology:Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 2Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 3Dyadic International Engages The Abraham Group as Strategic Advisor 2Dyadic International Engages The Abraham Group as Strategic Advisor 3Dyadic International Engages The Abraham Group as Strategic Advisor 4OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 5
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014 /PRNewswire/ ... the publication of a study that pinpoints fine-scale differences ... the United States . Since immigrants ... the United States has served as ... study illuminates how American history and the ongoing mixing ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... species within a community and are commonly transmitted ... pathogen emergence and therefore has been considered as ... of agricultural importance. Many pathogens like malaria, Lyme ... hosts are commonly transmitted by vectors, and their ...
... Researchers at Yale, in collaboration with NIH researchers, have ... the immune system for detection of parasitic infections, leading ... these infections. , Published in the April 28 issue ... how infectious parasites interface with the immune system--a problem ...
... shows that farmers who used agricultural insecticides experienced ... longer using the products. Data from 18,782 North ... including organophosphates and organochlorines, to reports of reoccurring ... and other neurological symptoms. Some of the insecticides ...
Cached Biology News:A new study examines how shared pathogens affect host populations 2Yale researchers identify molecule for detecting parasitic infection in humans 2Use of Insecticides Linked to Lasting Neurological Problems for Farmers 2
Values of steady state parameters for enzyme activities are determined....
... (PPAR) is a member of a ... factors that heterodimerize with retinoic acid-like ... the regulation of glucose and lipid ... of anti-diabetic agents called thiazolidinediones (TZD) ...
... This protein identification Service includes 1. ... protein spots 3. High-sensitive tryptic in-gel ... of samples for MALDI-MS 5. Acquisition ... via MALDI-MS (Bruker ultraflex TOF/TOF) 6. ...
... Preparation Reconstitution: one vial contains ... ficoll and 50 mg PVP; ... water yields a 50concentrate Special ... 1.00 g/mL (20 C) Quality ...
Biology Products: